Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640177 | 0.92 | PRKDC (0.72) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL17529474 | 0.88 | PRKDC (0.70) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL29976495 | 0.84 | PRKDC (0.74) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL25692518 | 0.84 | PRKDC (0.74) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL19640196 | 0.84 | LMNA (0.50) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL515642 | 0.83 | PRKDC (1.00) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL3371154 | 0.83 | ALDH1A1 (0.49) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL1620382 | 0.83 | LMNA (0.87) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL14835649 | 0.83 | LMNA (0.87) | PRKDCLMNAMAPTALDH1A1HPGD | |
| SCHEMBL3369827 | 0.82 | ALDH1A1 (0.62) | PRKDCLMNAMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100052-B2 | — | — | 2018-10-16 | — | — | US | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| WO-2017205115-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| WO-2017205115-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100052-B2 | — | HAVCR2, PYGL, FABP1 | PRKDC 3625/4885LMNA 2295/4885MAPT 2634/4885 |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | HAVCR2, PYGL, OAT | PRKDC 3905/4885LMNA 2667/4885MAPT 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.